A modified growth hormone releasing hormone (GHRH) analogue. CJC-1295 with DAC (Drug Affinity Complex) has an extended half-life of 6-8 days due to albumin binding. Often combined with Ipamorelin for synergistic GH release.
CJC-1295 with DAC is used in performance settings as a way to chronically elevate growth hormone and IGF-1 levels without the cost and injection frequency of pharmaceutical HGH. The DAC modification extends the half-life from minutes to days, meaning one or two injections per week can produce sustained GH elevation throughout the week. It is used i...
CJC-1295 with DAC is most commonly paired with Ipamorelin because the two compounds target different aspects of GH release. CJC-1295 acts on the GHRH receptor while Ipamorelin acts on the ghrelin receptor, and stimulating both simultaneously produces synergistic GH release greater than either compound alone. This pairing is the most discussed GH pe...
Sustained rather than pulsatile GH elevation is physiologically different from natural GH secretion and the long-term implications of chronic GH elevation are not established. Natural GH is released in pulses, particularly during deep sleep, and the regulatory mechanisms built around that pulsatile ...